UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended July 31, 2022. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 30, 2022. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended January 31, 2022. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 31, 2021. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended July 31, 2021. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | ...

Financial Performance - The consolidated net loss attributable to Rafael Holdings, Inc. was $2,553 thousand for the three months ended April 30, 2021, compared to a net loss of $2,159 thousand for the same period in 2020, an increase of 18%[170] - The Pharmaceuticals segment reported a loss from operations of $1,417 thousand for the three months ended April 30, 2021, compared to a loss of $778 thousand for the same period in 2020, representing an increase of 82%[165] - The Real Estate segment experienced a loss from operations of $2,062 thousand for the three months ended April 30, 2021, compared to a loss of $1,187 thousand for the same period in 2020, marking a 74% increase[167] Research and Development - Research and development expenses in the Pharmaceuticals segment increased by 99% to $1,262 thousand for the three months ended April 30, 2021, compared to $634 thousand in the same period in 2020[165] - The Pharmaceuticals segment has not generated any revenues to date, with all expenses related to various pharmaceutical activities[165] Cash Flow and Investments - As of April 30, 2021, the company had cash and cash equivalents of $4.7 million and investments in hedge funds amounting to $9.7 million, expected to meet working capital and R&D needs for the next 12 months[175] - For the nine months ended April 30, 2021, cash used in operating activities was $(8,620) thousand, an increase from $(2,975) thousand for the same period in 2020[176] - Cash used in investing activities for the nine months ended April 30, 2021 was primarily due to purchasing 7.3 million shares of Rafael Pharmaceuticals' Series D Preferred Stock for $9.1 million[178] - Cash provided by financing activities for the nine months ended April 30, 2021 was $15,770 thousand, primarily from the sale of 567,437 shares of Class B common stock[176] Impairment and Gains - The company recorded an impairment expense of $7.0 million related to its investment in Altira for the nine months ended April 30, 2021[165] - The company incurred an impairment expense related to the investment in Altira of $7.0 million for the nine months ended April 30, 2021[177] - The company recognized a gain on the sale of a building in Piscataway, New Jersey, amounting to approximately $749 thousand[171] - Unrealized gains on investments in hedge funds were approximately $4.2 million for the nine months ended April 30, 2021, compared to $492 thousand for the same period in 2020, reflecting a 748% increase[173] Operating Expenses - Selling, general and administrative expenses increased by 47% to $2,852 thousand for the three months ended April 30, 2021, compared to $1,937 thousand for the same period in 2020[168] Dividend Policy - The company does not anticipate paying dividends until achieving sustainable profitability and retaining minimum cash reserves[181] COVID-19 Impact - The ongoing COVID-19 pandemic has not had a material impact on the company's operations as of October 31, 2020, but the situation remains uncertain[182] - The company actively monitors the impact of COVID-19 on its operations and those of its holdings, particularly in clinical trials conducted in Europe and Asia[183] Shelf Registration - The company filed a Shelf Registration on Form S-3 on May 27, 2021, authorizing the sale of up to $250 million of Class B common stock[175]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended January 31, 2021. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 82-2296593 (State or other jurisdiction of incorporation or organization) (I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 31, 2020. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended July 31, 2020. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | ...

Financial Performance - Consolidated net loss attributable to Rafael Holdings, Inc. was $2,159,000 for the three months ended April 30, 2020, representing a 115% increase compared to the net loss of $1,005,000 for the same period in 2019[152]. - The company incurred a loss before income taxes of $5,252,000 for the nine months ended April 30, 2020, a 107% increase from the loss of $2,534,000 for the same period in 2019[153]. - Loss from operations for the Pharmaceuticals segment increased by 150% to $778,000 for the three months ended April 30, 2020 compared to $311,000 for the same period in 2019[146]. - Selling, general and administrative expenses for the nine months ended April 30, 2020 increased by approximately $949,000 (18%) compared to the same period in 2019, primarily due to increased payroll and bonus payments[148]. - The Pharmaceuticals segment has not generated any revenues to date, with expenses increasing due to the commencement of operations at Barer, resulting in a 1,209% increase in selling, general and administrative expenses for the three months ended April 30, 2020 compared to the same period in 2019[145]. Revenue and Expenses - The Real Estate segment experienced a revenue decrease of approximately $153,000 (39%) for the three months ended April 30, 2020, while revenues increased by approximately $141,000 (11%) for the nine months ended April 30, 2020 compared to the same period in 2019[147]. - Cash used in operating activities was $2,975,000 for the nine months ended April 30, 2020, compared to $2,538,000 for the same period in 2019, reflecting increased operations at the Barer Institute[158]. - Rental revenue from third-party tenants decreased by 39% to $360,000 for the three months ended April 30, 2020 compared to $588,000 for the same period in 2019[150]. - The company recorded an impairment loss of $295,000 related to investments in other pharmaceuticals for the nine months ended April 30, 2020[155]. Cash Position - Cash and cash equivalents as of April 30, 2020 were $8.4 million, expected to be sufficient for working capital, research and development, and capital expenditure requirements over the next twelve months[157]. - Cash used in financing activities for the nine months ended April 30, 2020, was primarily due to tax payments related to shares withheld for employee taxes on restricted stock vesting, net of proceeds from option exercises[161]. - The company does not anticipate paying dividends on common stock until achieving sustainable profitability and maintaining certain minimum cash reserves[161]. COVID-19 Impact - As of April 30, 2020, COVID-19 has not had a material impact on the company's operations, and existing cash balances are expected to satisfy operating requirements for at least the next twelve months[162]. - The company actively monitors the COVID-19 outbreak and its potential impact on operations, particularly for pharmaceutical holdings conducting activities in Europe and Asia[163]. - Clinical trial activities for pharmaceutical holdings have been managed to minimize disruptions, with collaboration from regulatory agencies[164]. - The company has implemented a mandatory work-from-home policy for employees who can perform their jobs remotely, along with restrictions on business travel and in-person meetings[165]. - The evolving nature of COVID-19 presents risks that could adversely impact operations, financial condition, and cash flows, with uncertainties regarding the pandemic's duration and severity[166]. - The potential economic impact of COVID-19 may reduce the company's ability to access capital, negatively affecting long-term liquidity[172]. Accounting and Financial Reporting - There have been no material changes in critical accounting policies and estimates during the nine months ended April 30, 2020[168]. - The company does not have any off-balance sheet arrangements that could affect financial condition or results of operations[169].